AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00957164 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Prolonged Exposure Protocol
Description: The PTSD treatment used in this study is an adaptation of a brief Prolonged Exposure treatment protocol for PTSD as illustrated in a 2005 paper published by Cigrang, Peterson, and Schobitz 54 in which a 4-session prolonged exposure treatment was used to address PTSD symptoms in three injured soldiers recently exposed to trauma. The authors found a 50+% decrease in PTSD symptoms after these four sessions. The present study will rely upon a similar brief PTSD intervention for treating chronic PTSD among trauma-exposed injured active duty service members. The PTSD intervention will be expanded into five sessions over 5 weeks to include an initial session for assessment and education on the co-morbidity of pain and PTSD. All PTSD treatment will be provided under the direct care or supervision of a Master Trained therapist in Prolonged Exposure.
Study NCT00957164 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Pain Management Treatment
Description: Pain treatment will involve five-sessions over 5 weeks of individual treatment protocol based on the existing chronic pain management program through the Clinical Health Psychology Service at Wilford Hall Medical Center. This treatment will involve covering the difference between chronic and acute pain, the role of cognitive, behavioral, and emotional variables in pain progression, and ways to manage these variables to prevent the development of chronic pain.
Study NCT00957164 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Care
Description: participants randomized to either the Pain-only or PTSD-only groups will receive five sessions of pain- or PTSD-specific treatment followed by five sessions of self-care placebo over 5 weeks. The self-care module will be manualized for reliability and fidelity between providers and will involve 60-minute sessions covering various topics.
Study NCT01719900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pulse fibre
Description: Yellow pea hull fibre incorporated into a biscuit at 5 g/serving.
Study NCT01719900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control biscuit with no yellow pea hull fibre.
Study NCT00786890 — intervention group
Intervention type: OTHER
Intervention: observational, no intervention needed
Description: observational, no intervention needed
Study NCT04453241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP615
Description: Intramuscular injection, 0.5ml
Study NCT04453241 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil
Description: Intramuscular injection, 0.5ml
Study NCT01639794 — intervention group
Intervention type: DRUG
Intervention: Vesitirim™ (Solifenacin)
Description: Oral
Study NCT01679613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: low or medium dose depending on pilot part
Study NCT01679613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: low dose oral administration
Study NCT04032379 — intervention group
Intervention type: OTHER
Intervention: Standard treatment
Description: No intervention, some patients have additional neuro-psychological testing.
Study NCT00514046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: once daily continuously (28 day cycles)
Study NCT03029260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mobilization - tension.
Description: Neural mobilization in tension consists of using combinations of joint movement known to maximize the tension and lengthening of peripheral nervous structures.~The intervention will be delivered in one session only.
Study NCT03029260 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neural mobilization - gliding
Description: Gliding neural mobilization consists of using combinations of joint movement known to maximize the movement of the peripheral nerves in relation to adjacent structures.~The intervention will be delivered in one session only.
Study NCT04152850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Medicine
Description: Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep and Traditional Chinese Medicine
Study NCT04737213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGM-101
Description: Fluorescence guided surgery
Study NCT03225846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-120102
Description: WVE-120102 is a stereopure antisense oligonucleotide (ASO)
Study NCT03225846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride
Study NCT03695016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ActiveGOALs
Description: 13 week, online self-directed intervention. Once weekly sessions are based on social-cognitive theory models of behavior changes. Coaches will provide weekly feedback . Behavior tracking tools will be provided. Links to tools that support physical activity will also be provided.
Study NCT03695016 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ActiveGOALs
Description: 13 week, online self-directed intervention. Once weekly sessions are based on social-cognitive theory models of behavior changes. Coaches will provide weekly feedback . Behavior tracking tools will be provided. Links to tools that support physical activity will also be provided.
Study NCT03072758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Men's Club
Description: Interactive session: This will be a one-day five-hour session that will take place at the church, and will be facilitated by trained lactation nurses. This will involve a maximum of 10 male participants and will occur during the female partner's 3rd trimester. Male partners will (a) complete a structured questionnaire to determine baseline knowledge, attitudes and beliefs about breastfeeding practices, and (b) actively engage in educational information on the benefit of exclusive breastfeeding. At the end of the session, the participants will receive educational pamphlets on breastfeeding to reinforce all the information that had been provided.~Phone call reminders: Participants will receive weekly robocalls during the first six weeks following the birth of the infant to reinforce the benefits of exclusive breastfeeding. This will be an automated service that will deliver the calls at a specific time of the day the participants have indicated on their questionnaire.
Study NCT02855164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropifexor (LJN452)
Description: Comparison of different doses of drug
Study NCT02855164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator
Study NCT03135704 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Re Spine
Description: A new mattress design made of special materials and built in a specially shaped structure that allows the brain to relax the body and dissipate tension accumulated on the lumbar spine.
Study NCT03135704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Usual protocol for treatment of low back pain
Study NCT04380337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: Chemotherapy regimen of Oxaliplatin 85mg/m2 , Leucovorin 400 mg/m2 , Irinotecan 165mg/m2 , 5-Fluorouracil
Study NCT04380337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Chemotherapy regimen of Oxaliplatin 85mg/m2, Leucovorin 400 mg/m2, 5-Fluorouracil 2400mg/m2
Study NCT04380337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Chemotherapy regimen of Oxaliplatin 130 mg/m2, Capecitabine 1000mg/m2
Study NCT04380337 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Radiotherapy (5 Gy x 5 fractions) with an additional boost fraction (5 Gy x 1 fraction) delivered sequentially
Study NCT01082146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: 40 mg suspension, PO, for 7 days
Study NCT01865123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation
Description: A standard 7 step course will be offered including an introductory and preparatory lectures, personal one-on-one instruction with a certified TM teacher followed by 3 consecutive days of classes on how to meditate correctly and effortlessly, how to understand mechanisms of stress release and sequential development to higher levels of human consciousness and enjoying ones full potential. Followup meetings will provide checking of TM practice, sharing of group experiences with the TM practice and knowledge to motivate and inspire continued regularity with the practice. The certified TM instructor will have experience with PTSD in this veteran population.
Study NCT01865123 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure
Description: Prolonged exposure therapy, a specific form of cognitive behavioral therapy, is considered the standard psychotherapy treatment for PTSD . The delivery of PE will be by a trained study therapist. There will be 16 individual sessions provided to each participant. Homework will include relaxation and breathing exercises and anxiety diaries.
Study NCT01865123 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Educational control
Description: This group will receive group-administered didactic health education specific to the PTSD veterans population. It will include emphasis on healthy lifestyle changes to promote more positive mental and physical health. The classes will be matched with the TM and PE interventions to control for time, instructor attention and other non-specific factors.
Study NCT02500875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTNiA
Study NCT02500875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTNiB
Study NCT02500875 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTN
Study NCT03084939 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) was administered intravenously on Day 1 of each 21-day cycle.
Study NCT03084939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Description: Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.
Study NCT03084939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 milligrams per square meter (mg/m\^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
Study NCT02225821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalozin
Description: 1000 mg Cephalozin
Study NCT02225821 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: 10 cc of NaCl 0.9%
Study NCT04282590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-750/Placebo
Description: Powder for oral solution
Study NCT04282590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo/TRK-750
Description: Powder for oral solution
Study NCT01234766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90mg/m2, IV - Days 1 and 2 of every cycle
Study NCT01234766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2, IV - Cycle 1 only: Day -7 (+1 day) Day 1 of every cycle
Study NCT01234766 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Y-90 ibritumomab
Description: 0.4mCi/kg, IV - Within 4 hours of rituximab, give over 10 minutes
Study NCT02495896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT02495896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT02495896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT02495896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02495896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Description: Given IV
Study NCT02495896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02495896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant EphB4-HSA Fusion Protein
Description: Given IV
Study NCT03918954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual sensory room
Description: A pair of virtual reality glasses (Oculus Go) with installed the program Calm Place, a program designed for anxiety reduction.
Study NCT03918954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensory room
Description: A room with calming elements that patients can use to feel calm.
Study NCT01212406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Every month 100.000 units of vitamin D in syringe Exacta-Med Oral Dispenser during 2 years and re-evaluation after 3 years
Study NCT01212406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Every month 100.000 units of vitamin D in syringe Exacta-Med Oral Dispenser during 2 years and re-evaluation after 3 years
Study NCT02327819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Branched-chain amoni acids (BCAA)
Study NCT02327819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: non-BCAA protein supplement
Study NCT03399149 — intervention group
Intervention type: OTHER
Intervention: Systematic evaluation by an intensivist
Description: implementation of a standardized procedure for patient care in ICU
Study NCT00641186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium oxybate
Description: 4.5 to 9.0 grams per night
Study NCT01939782 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Breakfast (NoB)
Description: In both occasions the blood samples for glucose and insulin, cortisol triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).
Study NCT01939782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Breakfast (NoB)
Description: In both occasions the blood samples for glucose and insulin, cortisol triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).
Study NCT01939782 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yes Breakfast (YesB)
Description: In both occasions the blood samples for glucose and insulin, cortisol, triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and then at 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).
Study NCT01939782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yes Breakfast (YesB)
Description: In both occasions the blood samples for glucose and insulin, cortisol, triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and then at 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).
Study NCT03509792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple cognitive task
Description: A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1.
Study NCT03509792 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention placebo
Description: Smartphone activity for same amount of time.
Study NCT03331627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: STR001-IT and STR001-ER
Description: STR001-IT intrataympanic injection and STR001-ER tablet
Study NCT03331627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: STR001-IT and STR001-ER
Description: STR001-IT intrataympanic injection and STR001-ER tablet
Study NCT03691285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular Overdenture
Description: Placement of 1 or 2 implants in the anterior region of the edentulous mandible.
Study NCT03691285 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular Overdenture
Description: Placement of 1 or 2 implants in the anterior region of the edentulous mandible.
Study NCT02071550 — intervention group
Intervention type: DEVICE
Intervention: FORESİGHT cerebral oxygen monitor and INVOS cerebral oxygen monitor
Study NCT02071550 — intervention group
Intervention type: DEVICE
Intervention: FORESIGHT and INVOS monitor
Study NCT01235130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OMEGA-3
Description: 600mg, 2 caps, twice a day
Study NCT01235130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo soybean oil
Description: 600mg, 2caps twice a day
Study NCT00798031 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: A minimum of two but up to three Astra Tech Dental Implant, Fixture Osseospeed will be placed in the posterior upper jaw of 20 eligible subjects.
Description: A minimum of 2 but up to three dental implants will be placed in the posterior upper jaw of 20 subjects. The dental implants are produced by Astra Tech AB (Fixture Micro Thread OsseoSpeed TM Astra Tech AB. The study will include 15 clinic visits and interim analysis will occur at 6 months, 1, 2, and 3 years after loading of the temporary prosthesis.
Study NCT00798031 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Placement of dental implant
Description: Device: A minimum of two but up to three Astra Tech Dental Implant, Fixture Osseospeed will be placed in the posterior upper jaw of 20 eligible subjects.~A minimum of 2 but up to three dental implants will be placed in the posterior upper jaw of 20 subjects. The dental implants are produced by Astra Tech AB (Fixture Micro Thread OsseoSpeed TM Astra Tech AB. the study will include 15 clinic visits and interim analysis will occur at 6 months, 1, 2, and 3 years after loading of the temporary prothesis.
Study NCT00798031 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: dental implant
Description: Subjects will have a complete diagnostic work-up performed and assessment for eligibility in the study by both a Prosthodontist and Surgeon. Subjects will then have two and up to three dental implants placed in an out patient basis at the University of Iowa College of Dentistry
Study NCT05433896 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dasatinib ASD
Description: XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 90 mg Test Formulation
Study NCT05433896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib ASD
Description: XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 90 mg Test Formulation
Study NCT05433896 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole 40 MG
Description: Omeprazole Delayed Release Capsules, USP 40 mg
Study NCT03796013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib Form A
Description: Participants will receive a single oral dose of entrectinib form A under fasted conditions.
Study NCT03796013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib Form C
Description: Participants will receive a single oral dose of entrectinib form C under fasted conditions.
Study NCT01213862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Based Education
Description: There will provided education about what is heart failure, its causes, how to recognize signs and symptoms, monitoring of weight and blood pressure, the importance of compliance to treatment. Patients will be instructed about the medications; a guide to rest and exercise, sexual activity, vaccines, travel and diet will be provided. The involvement of the family will be encouraged; the contact with the team should be done when: patient observes an increase of 1 or 2 kg of weight in 2-3 days, worsening of dyspnea on effort, edema in legs / abdomen, worsening of cough, persistent vomiting, syncope, sputum with blood, fever, persistent tachycardia. In phone calls made between home visits, the compliance to treatment will be evaluated and reinforced.
Study NCT04421937 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Procedure: Traditional Dysphagia Therapy (TDT)
Description: Traditional dysphagia therapy includes diet modification training, teaching postural compensatory methods, training of oral motor control exercises and tongue root exercises, training of swallowing maneuvers, and practice of chin-resistance exercise, which is the exercise of opening the upper esophageal sphincter.~Traditional Dysphagia Therapy will be applied for 45 minutes a day, 5 days a week for 3 weeks.